Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 12
Submit an article Journal homepage
127
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Durable response to ivosidenib in post-transplant relapse and leukemic transformation of myelodysplastic syndrome with new complex karyotype and IDH1 R132C mutation

Hanan Alkhaldia University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA;b Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USAView further author information
,
Danielle Sewellc Translational Genomics Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USAView further author information
,
Yi Ningd Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USAView further author information
,
Michael E. Kallend Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USAView further author information
,
Ashkan Emadia University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA;b Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA;c Translational Genomics Laboratory, University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USAView further author information
,
Nancy M. Hardya University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA;b Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USAView further author information
&
Maria R. Baera University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA;b Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USACorrespondence[email protected]
View further author information
 show all
Pages 3000-3003 | Received 13 Jun 2022, Accepted 14 Jul 2022, Published online: 08 Aug 2022

References

  • Cazzola M. Myelodysplastic syndromes. N Engl J Med. 2020;383(14):1358–1374.
  • Schanz J, Cevik N, Fonatsch C, et al. Detailed analysis of clonal evolution and cytogenetic evolution patterns in patients with myelodysplastic syndromes (MDS) and related myeloid disorders. Blood Cancer J. 2018;8(3):28.
  • Mossner M, Jann JC, Wittig J, et al. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure. Blood. 2016;128(9):1246–1259.
  • Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366(12):1090–1098.
  • Horowitz M, Schreiber H, Elder A, et al. Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplant. 2018;53(11):1379–1389.
  • Schmid C, de Wreede LC, van Biezen A, et al. Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the chronic malignancies working party of the European Society of Blood and Marrow Transplantation. Haematologica. 2018;103(2):237–245.
  • DiNardo CD, Stein EM, de Botton S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378(25):2386–2398.
  • Nakamura R, Saber W, Martens MJ, et al. Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50–75 years of age with advanced myelodysplastic syndrome. J Clin Oncol. 2021;39(30):3328–3339.
  • Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120(12):2454–2465.
  • Jacoby MA, Duncavage EJ, Chang GS, et al. Subclones dominate at MDS progression following allogeneic hematopoietic cell transplant. JCI Insight. 2018;3(5):e98962.
  • Quek L, Ferguson P, Metzner M, et al. Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia. Blood Adv. 2016;1(3):193–204.
  • Stein EM, DiNardo CD, Fathi AT, et al. Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Blood. 2019;133(7):676–687.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.